The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
JHFH - even though we've had a few differences of opinion, I agree with a lot of what you post. My main issue is that you find it impossible to bin the twats on here. By replying to them, you give them a voice for them to peddle their nonsense and this in turn makes the board unreadable at times. I'm comfortable with my position and an prepared to wait - unlike many on here.
Good - you had me worried there for a moment. IMO, if the treatment does get approved after successful trials, it will not been under Hemogenyx control - we will be bought out or Car-T will be sold to fund the development of CBR.
DCT - how can you expect clinical trials to be have been nearly sorted prior to clinical hold lift. Are you saying we should have had a raft of patients ready to go - when we didn't know 100% that it would be lifted ? How do you think those patients would have felt if they were then let down ?
Yes they do but I doubt anyone on these boards would possess any. From the November RNS :
Queeld Ventures Limited and Mispare Limited (respectively "Queeld" and "Mispare") are registered shareholders in Eurasia Mining PLC ("Eurasia"). In or about July 2018, Queeld and Mispare applied to Eurasia for the issue of replacement share certificates in respect of their respective shareholdings.
Datta- “he loves Russia and its people” - that one comment is enough to put you in the bin.
As long as his people do exactly as he commands they’ll be fine but step out of line and ….. the rest is history. No freedom of speech and those who do speak freely find themselves falling out of a very high window. Binned
Currently on hols so only have my Ipad and when I try to download I get a load of text which is unreadable - see below. I’m a pharmacist so know exactly who constitutes big pharma.
id":"J14124"},"secondaryIdInfos":[{"id":"IRB00046315","type":"OTHER","domain":"JHMIRB"},{"id":"P50CA103175","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P50CA103175"}],"organization":{"fullName":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","class":"OTHER"},"briefTitle":"Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET","officialTitle":"Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET"},"statusModule":{"statusVerifiedDate":"2023-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-02-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-05-01","type":"ACTUAL"},"completionDateStruct":{"date":"2022-05-01","type":"ACTUAL"},"studyFirstSubmitDate":"2015-01-13","studyFirstSubmitQcDate":"2018-05-18","studyFirstPostDateStruct":{"date":"2018-05-31","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-01-09","lastUpdatePostDateStruct":{"date":"2023-01-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"To use 18F-DCFPyL imaging agent and PET/CT to detect none prostate cancer solid malignancies and schwannoma tumors.","detailedDescription":"The purpose of this protocol is to extend our existing patient base from those with prostate cancer to those with any solid
D-Geeman- “ but if he spilts off the DX side then that only leave the precision platform”- this is not correct. He can split off the DX side and still keep the Affimer platform. He can then license it out.
“ Think we all know that most of these studies were run by big pharma”. - you can’t possibly know that JHFH. It’s a pure guess on your part. You shouldn’t promote your opinion as fact.
I do agree that Vlad will be hopefully be looking to license as soon as possible though.
JHFH - below is a link to info on clinical trial costs. Average cost for a phase 1 trial is 4.5m and this was in 2015 / 16 so likely higher now.
https://www.sofpromed.com/how-much-does-a-clinical-trial-cost